Eurofins Scientific Shares Close Above 20-Day Moving Average
Eurofins Scientific shares closed the Wednesday, January 28 session at 70.62 euros, down 0.87% from the previous day. However, the stock of the European leader in laboratory testing and analysis shows a strong momentum over the past months, with a gain of 14.68% over three months and 42.72% over one year.
Technically, Eurofins Scientific is trading above its 20-day moving average, which is positioned at 69.39 euros. This positioning indicates a favorable short-term trend, despite a slight decline during the session. The stock also benefits from sustained momentum over the past week, with a progression of 0.37%. The Relative Strength Index (RSI) stands at 60, indicating some dynamism without signaling overheating. The one-month volatility is set at 9.70, which is moderate for the sector. The current technical configuration thus suggests potential for a short-term upward movement, provided that the support from the 20-day moving average continues.
Investment House Forecasts
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Several investment houses have recently adjusted their forecasts for the stock. Kepler Cheuvreux raised its price target from 72 to 81 euros in mid-January, representing a potential progression of 14.7% from the current level. This upward revision follows several quarters of solid operational performance as perceived by analysts. Meanwhile, Morgan Stanley also revised its valuation in early January, raising its target from 61 to 64 euros, while maintaining a market-weight recommendation. These consecutive adjustments reflect a generally positive appreciation of the stock's fundamentals by market professionals.
SectorSanté · Vaccins et laboratoires de recherche›Services médicaux
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1789M€
Guidance from the release
Eurofins a rencontré des vents contraires importants et temporaires.
Malgré une croissance organique modérée, la rentabilité et les marges progressent.
Risks mentioned
Baisse de la demande en raison de conditions climatiques défavorables en Amérique du Nord.
Rationalisation des contrats dans les diagnostics cliniques en Espagne et en Italie.
Opportunities identified
Lancement de nouveaux contrats renforçant notre portefeuille BioPharma.
Initiatives de digitalisation et amélioration du réseau de laboratoires.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
